Incyte
INCYTE CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$5.1B
Operating marginCalculated
29.5%
Net assets to total assetsCalculated
74.3%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★★position among all companies
29.5%
Growth (revenue, 4-year average)
★★★★★position among all companies
14.5%
Capital efficiency
★★★★☆position among all companies
24.9%
Revenue and profit
Performance, financial position and capital allocation
Incyte
Recent performance trends
Incyte
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$3.0 billion | US$3.4 billion | US$3.7 billion | US$4.2 billion | US$5.1 billion |
| Operating income | US$0.6 billion | US$0.6 billion | US$0.6 billion | US$61.37 million | US$1.5 billion |
| Net income | US$0.9 billion | US$0.3 billion | US$0.6 billion | US$32.62 million | US$1.3 billion |
| Total assets | US$4.9 billion | US$5.8 billion | US$6.8 billion | US$5.4 billion | US$7.0 billion |
| Shareholders' equity | US$3.8 billion | US$4.4 billion | US$5.2 billion | US$3.4 billion | US$5.2 billion |
| Net cash provided by (used in) operating activities | US$0.7 billion | US$1.0 billion | US$0.5 billion | US$0.3 billion | US$1.4 billion |
| Net cash provided by (used in) investing activities | US$-0.2 billion | US$-78.54 million | US$-0.2 billion | US$0.2 billion | US$-0.1 billion |
| Net cash provided by (used in) financing activities | US$6.18 million | US$-0.79 million | US$-20.03 million | US$-2.0 billion | US$0.1 billion |
| Cash and cash equivalents | US$2.1 billion | US$3.0 billion | US$3.2 billion | US$1.7 billion | US$3.1 billion |
Revenue scale in the same industry
Incyte
Engineering, accounting, research and management services: 11 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Iqvia HoldingsFY Dec 2025 US$16.3B
- 2 AecomFY Sep 2025 US$16.1B
- 3 Booz Allen Hamilton HoldingFY Mar 2026 US$11.2B
- … 1 companies
- 5 GartnerFY Dec 2025 US$6.5B
- 6 Tetra TechFY Sep 2025 US$5.4B
- 7 IncyteThis companyFY Dec 2025 US$5.1B
- 8 V2XFY Dec 2025 US$4.5B
- 9 Charles River Laboratories InternationalFY Dec 2025 US$4.0B
- … 2 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Cash and cash equivalents | US$3.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.4 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$93.29 million | Consolidated | Disclosed |
| Net assets | US$5.2 billion | Consolidated | Disclosed |
| Net sales | US$5.1 billion | Consolidated | Disclosed |
| Operating income | US$1.5 billion | Consolidated | Disclosed |
| Net income | US$1.3 billion | Consolidated | Disclosed |
| Total assets | US$7.0 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0 | Consolidated | Disclosed |
| Operating margin | 29.5% | Consolidated | Calculated |
| Net assets to total assets | 74.3% | Consolidated | Calculated |
| Net margin | 25.0% | Consolidated | Calculated |
| Return on equity | 24.9% | Consolidated | Calculated |